402 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
, compared with $8.5 million for the same period in 2022. Research and development expenses were $5.5 million for the fourth quarter of 2023, compared … . Amortization of intangibles was $33.7 million for 2023, compared with $34.2 million for 2022. Research and development expenses were $24.5 million
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
million for the nine months ended September 30, 2023, compared with $25.7 million for the same period in 2022. Research and development expense …
Research and development
General and administrative
Total operating costs and expenses
Gain on sale of Pelican
Income (loss) from operations
Gain
8-K
EX-99.1
ofh68h lgi
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
weklg8g2qk
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
gojzah439hjivv0wqd
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
ejg01 3jm
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
8-K
EX-99.1
e4r0v2 dh3u7740j
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
8-K
EX-99.1
0r7cy6 c5pr
8 Aug 22
Ligand Reports Second Quarter 2022 Financial Results
4:06pm
425
EX-99.1
mwh360df
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
mq65n428 xv
21 Jun 22
Regulation FD Disclosure
6:19am
425
0be39yyqhl7j19t8aa
5 May 22
Business combination disclosure
7:30am
8-K
EX-99.1
4ozm3f8hp6
4 May 22
Ligand Reports First Quarter 2022 Financial Results
4:03pm